Discovery of 2-phenyl-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl) acetamide derivatives as apoptosis inducers via the caspase pathway with potential anticancer activity

Archiv der Pharmazie

Volumn 346, Issue 11, 2013, Pages 812-818

  Hosseinzadeh, Leila ^a   Khorand, Amanc ^a,b   Aliabadi, Alireza ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1,3,4 Thiadiazole; Anticancer; Apoptosis; Caspase enzymes; Synthesis

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; 2 (2 CHLOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (2 FLUOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (2 HYDROXYPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (2 METHOXYPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (2 NITROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (3 CHLOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (3 FLUOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (3 HYDROXYPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (3 METHOXYPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (4 BROMOPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (4 CHLOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (4 FLUOROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (4 METHOXYPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 (4 NITROPHENYL) N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 2 O TOLYL N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; DOXORUBICIN; N [5 (TRIFLUOROMETHYL) 1,3,4 THIADIAZOL 2 YL] 2 [4 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; UNCLASSIFIED DRUG; 1,3,4-THIADIAZOLE; CASPASE; ENZYME ACTIVATOR; THIADIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VITRO STUDY; MELTING POINT; NEUROBLASTOMA; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; CELL SURVIVAL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; IC50; MALE; MCF 7 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL SURVIVAL; DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MCF-7 CELLS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 84887493189     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201300180     Document Type: Article

References (33)

1. A. Lawen, Bioessays 2003, 25, 888-896.
2. G. Kaushik, T. Kaushik, S. Khanduja, C. M. Pathak, K. Khanduja, Cancer Lett. 2008, 270, 120-131.
3. T. Albreht, M. Mckee, D. M. Alexe, M. P. Coleman, J. M. Martin-Moreno, Eur. J. Cancer 2008, 44, 1451-1456.
4. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, P. Boyle, Ann. Oncol. 2007, 18, 581-592.
5. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun, Cancer J. Clin. 2006, 56, 106-130.
6. H. A. Bhuva, S. J. Kini, J. Mol. Graph. Model. 2010, 29, 32-37.
7. S. Madhusudan, S. Trivadi, T. S. Ganesan, Clin. Biochem. 2004, 37, 618-635.
8. I. M. Ghobrial, T. E. Witzig, A. A. Adjei, CA Cancer J. Clin. 2005, 55, 178-194.
9. D. Sunil, A. M. Isloor, P. Shetty, K. Satyamoorthy, A. S. Bharath Prasad, Arab. J. Chem. 2010, 3, 211-217.
10. H. Rajak, R. Deshmukh, N. Aggarwal, S. Kashaw, M. D. Kharya, P. Mishra, Arch. Pharm. Chem. Life Sci. 2009, 342, 453-461.
11. M. Abdel-Aziz, O. M. Aly, S. S. Khan, K. Mukherjee, S. Bane, Arch. Pharm. Chem. Life Sci. 2012, 345, 535-548.
12. X. Q. Deng, Z. Q. Dong, M. X. Song, B. Shu, S. B. Wang, Z. S. Qua, Arch. Pharm. Chem. Life Sci. 2012, 345, 565-573.
13. S. A. F. Rostom, M. H. Badr, H. A. Abd El Razik, H. M. A. Ashour, A. E. Abdel Wahab, Arch. Pharm. Chem. Life Sci. 2011, 344, 572-587.
14. G. Mishra, A. K. Singh, K. Jyoti, Int. J. ChemTech Res. 2011, 3, 1380-1393.
15. A. K. Singh, G. Mishra, K. Jyoti, J. Appl. Pharm. Sci. 2011, 5, 44-49.
16. R. Kharb, P. Kaur, P. C. Sharma, M. S. Yar, Int. J. Res. Pharm. Biomed. Sci. 2011, 4, 1520-1540.
17. U. Kalidhar, A. Kaur, Res. J. Pharm. Biol. Chem. 2011, 4, 1091-1106.
18. N. Siddiqui, P. Ahuja, W. Ahsan, S. N. Pandeya, M. S. Alam, J. Chem. Pharm. Res. 2009, 1, 19-30.
19. S. K. Ardestani, F. Poorrajab, S. Razmi, A. Foroumadi, S. Ajdary, B. Gharegozlou, M. Behrouzi-Fardmoghadam, A. Shafiee, Exp. Parasitol. 2012, 32, 116-122.
20. D. Kumar, B. Reddy, K. H. Vaddula, K. H. Chang, K. Shah, Bioorg. Med. Chem. Lett. 2011, 21, 2320-2323.
21. N. N. Farshori, R. M. Banday, A. Ahmad, A. U. Khan, A. Rauf, Bioorg. Med. Chem. Lett. 2010, 20, 1933-1938.
22. J. Matysiak, A. Opolski, Bioorg. Med. Chem. 2006, 14, 4483-4489.
23. M. Yusuf, P. Jain, Arab. J. Chem. 2011, in press.
24. W. Rzeski, J. Matysiakb, M. Kandefer-Szerszen, Bioorg. Med. Chem. 2007, 15, 3201-3207.
25. J. Y. Chou, S. Y. Lai, S. L. Pan, G. M. Jow, J. M. Chern, J. H. Guh, Biochem. Pharmacol. 2003, 66, 115-124.
26. D. A. Ibrahim, Eur. J. Med. Chem. 2009, 44, 2776-2781.
27. C. T. Supuran, A. Scozzafava, Eur. J. Med. Chem. 2000, 35, 867-874.
28. X. H. Yang, Q. Wen, T. T. Zhao, J. Sun, X. Li, M. Xing, X. Lu, H. L. Zhu, Bioorg. Med. Chem. 2012, 20, 1181-1187.
29. I. Lalezari, N. Sharghi, J. Heterocyclic Chem. 1966, 3, 336-338.
30. A. Aliabadi, F. Shamsa, S. N. Ostad, S. Emami, A. Shafiee, J. Davoodi, A. Foroumadi, Eur. J. Med. Chem. 2010, 11, 5384-5389.
31. L. Hosseinzadeh, J. Behravan, F. Mosaffa, G. Bahrami, A. Bahrami, G. Karimi, Food. Chem. Toxicol. 2011, 49, 1102-1109.
32. D. Gerlier, N. Thomasset, J. Immunol. Methods 1986, 94, 57-63.
33. S. J. Riedl, Y. Shi, Nat. Rev. Mol. Cell. Biol. 2004, 5, 897-907.